@article {Acharyae000911, author = {Nandini Acharya and Catherine Sabatos-Peyton and Ana Carrizosa Anderson}, title = {Tim-3 finds its place in the cancer immunotherapy landscape}, volume = {8}, number = {1}, elocation-id = {e000911}, year = {2020}, doi = {10.1136/jitc-2020-000911}, publisher = {BMJ Specialist Journals}, abstract = {The blockade of immune checkpoint receptors has made great strides in the treatment of major cancers, including melanoma, Hodgkin{\textquoteright}s lymphoma, renal, and lung cancer. However, the success rate of immune checkpoint blockade is still low and some cancers, such as microsatellite-stable colorectal cancer, remain refractory to these treatments. This has prompted investigation into additional checkpoint receptors. T-cell immunoglobulin and mucin domain 3 (Tim-3) is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Coblockade of Tim-3 and PD-1 can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients. In this review, we will discuss the basic biology of Tim-3, its role in the tumor microenvironment, and the emerging clinical trial data that point to its future application in the field of immune-oncology.}, URL = {https://jitc.bmj.com/content/8/1/e000911}, eprint = {https://jitc.bmj.com/content/8/1/e000911.full.pdf}, journal = {Journal for ImmunoTherapy of Cancer} }